Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.76 |
---|---|
High | 12.76 |
Low | 11.98 |
Bid | 12.06 |
Offer | 12.36 |
Previous close | 12.29 |
Average volume | 209.30 |
---|---|
Shares outstanding | 91.16m |
Free float | 87.12m |
P/E (TTM) | -- |
Market cap | 1.17bn USD |
EPS (TTM) | -2.75 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Press releases
- Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
- Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
- Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
- Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
- Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
- Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
- Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
More ▼